The use of the drug mildronate in obstetrics

2021 ◽  
Vol 50 (4) ◽  
pp. 29-33
Author(s):  
N. G. Pavlova ◽  
E. I. Krivtsova ◽  
N. N. Konstantinova
Keyword(s):  
Positive Influence ◽  
Placental Insufficiency ◽  
Third Trimester ◽  
The Third

The report contains data on positive influence of mildronatum infusion (10% NaCl) on uterine-placental and fetoplacental circulation in women with chronic placental insufficiency in the third trimester of pregnancy.

METHOD FOR ASSESSING THE RISK OF FORMATION OF PLACENTAL INSUFFICIENCY IN CYTOMEGALOVIRUS INFECTION IN THE THIRD TRIMESTER OF GESTATION

2018 ◽  
Author(s):  
Наталия Ишутина ◽  
Nataliya Ishutina ◽  
Ирина Андриевская ◽  
Irina Andrievskaya ◽  
Инна Довжикова ◽  
...  
Keyword(s):  
Cytomegalovirus Infection ◽  
Placental Insufficiency ◽  
Third Trimester ◽  
The Third

scholarly journals Contemporary placentography: harm or benefit?

2019 ◽  
Vol 10 (1) ◽  
pp. 5-12 ◽  
Author(s):  
Vitaly F. Bezhenar ◽  
Lidiya A. Ivanova ◽  
Stepan G. Grigoriev ◽  
Elena V. Titkova
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Amniotic Fluid ◽  
Placental Insufficiency ◽  
Third Trimester ◽  
Control Groups ◽  
The Third ◽  
Maternity Hospitals ◽  
Screening Ultrasound ◽  
And Control

Currently, pediatricians, neonatologists of maternity hospitals often take part in perinatal consultations. One of the indications for early delivery may be chronic placental insufficiency diagnosed during an ultrasound examination. Objective: to evaluate the effectiveness of the main method of diagnosis of placental insufficiency at the present time – ultrasound evaluation of the placenta. Materials and methods. An analysis was made of 357 birth histories, exchange cards, protocols for screening ultrasound in the third trimester of pregnancy and conclusions of pathoanatomical investigation. Results. To substantiate the need for prenatal diagnosis of chronic kidney disease, a comparison was made of the evaluation of newborn babies on the Apgar scale and the state of the placenta according to histological data. With compensated chronic placental insufficiency, there was no difference in Apgar scores at the first and fifth minutes, whereas in the subcompensated stage, Apgar score on the Apgar scale was significantly lower in the first and fifth minutes than in the control group. To identify possible in practical use of the objective parameters of diagnosis of chronic kidney disease, the thickness of the placenta was measured during the screening ultrasound in the third trimester of pregnancy, as well as the thickness of the placenta after its separation. Significant differences in the thickness of the placenta or in the screening ultrasound, or when measuring the placenta after separation in patients with and without chronic placental insufficiency was not detected. When assessing a violation of the rate of maturation of the placenta in the third trimester of pregnancy, no significant differences were found in the presence and absence of placental insufficiency. An analysis of the amniotic index was carried out to determine the amount of amniotic fluid in patients of the main and control groups, which revealed no significant differences between the groups. Conclusions. The authors believe that the main indicators currently used for diagnosis of chronic placental insufficiency (thickness of the placenta, degree of maturity of the placenta, appearance of structural changes in the placenta, change in the amount of amniotic fluid) are uninformative and modern placenography does more harm than benefit. The only parameter determined during the screening study in the third trimester of pregnancy and having significant differences in the main and control groups is fetal hypotrophy.

scholarly journals THE ROLE OF CHOLESTEROL AND ESTRADIOL IN THE DEVELOPMENT OF PLACENTAL INSUFFICIENCY UNDER CYTOMEGALOVIRUS INFECTION IN THE THIRD TRIMESTER OF PREGNANCY

2017 ◽  
Vol 1 (65) ◽  
pp. 54-58
Author(s):  
Наталия Ишутина ◽  
Nataliya Ishutina ◽  
Михаил Луценко ◽  
Mikhail Lutsenko ◽  
Ирина Андриевская ◽  
...  
Keyword(s):  
Pregnant Women ◽  
Total Cholesterol ◽  
Discriminant Function ◽  
Cytomegalovirus Infection ◽  
Placental Insufficiency ◽  
Third Trimester ◽  
The Third ◽  
Limit Value ◽  
Period Of Gestation

To assess the role of cholesterol and estradiol in the development of placental insufficiency under cytomegalovirus infection (CMVI) in the period of gestation, cholesterol and estradiol were studied in the peripheral blood of 35 pregnant women who had a reactivation of chronic CMVI (IgG antibody titer to CMV is 1:1600) in the third trimester of pregnancy (the main group). As a control the blood plasma of 35 healthy women of the same period of gestation and age as in the main group were studied. It was found out that the reactivation of chronic CMVI in the third trimester of gestation was followed by the decrease of concentration of cholesterol by 23% ( p<0.001), of estradiol by 65% (p<0.001) in comparison with the values of healthy women. To analyze the chosen values for assessment, the discriminant function was found. It had the probability of differences not less than 95%; which that the discriminant equation was derived which for this study had the following formula: D=(-379×total cholesterol)+(-0.072×estradiol), where D is a discriminant function whose limit value is (-2673.59). If D is equal or less than the limit value, then the development of placental insufficiency in women in the third trimester of pregnancy is predicted, and if D is more than the limit value, then the normal course of the third trimester of pregnancy is predicted. Thus, the obtained results allow to establish the main role of disturbances of total cholesterol contents and key steroid hormone of pregnancy (estradiol) in the pathogenesis of placental insufficiency development under CMVI during gestation, which can be the basis for improvement of diagnostic and medical basis under this pathology of pregnant women.

Correlations Between the Values of Maternal Glycemia from the Last Trimester of Pregnancy and Fetal Birth Weight

2013 ◽  
Vol 20 (3) ◽  
pp. 259-265
Author(s):  
Monica Vereş ◽  
Aurel Babeş ◽  
Szidonia Lacziko
Keyword(s):  
First Trimester ◽  
Mean Value ◽  
Fetal Macrosomia ◽  
Entire Group ◽  
Third Trimester ◽  
The Third ◽  
Group I ◽  
Fetal Birth Weight ◽  
First Trimester Of Pregnancy ◽  
The Mean

Abstract Background and aims: Gestational diabetes represents a form of diabetes diagnosed during pregnancy that is not clearly overt diabetes. In the last trimester of gestation the growth of fetoplacental unit takes place, thus maternal hyperglycemia will determine an increased transplacental passage, hyperinsulinemia and fetal macrosomia. The aim of our study was that o analyzing the effect of maternal glycemia from the last trimester of pregnancy over fetal weight. Material and method: We run an observational study on a group of 46 pregnant women taken into evidence from the first trimester of pregnancy, separated in two groups according to blood glucose determined in the third trimester (before birth): group I normoglycemic and group II with hyperglycemia (>92mg/dl). Results: The mean value of third trimester glycemia for the entire group was of 87.13±22.03. The mean value of the glycemia determined in the third trimester of pregnancy was higher in the second group (109.17 mg/dl) in comparison to the first group (74.,21 mg/dl). The ROC curve for third trimester glycemia as fetal macrosomia appreciation test has an AUC of 0.517. Conclusions: Glycemia determined in the last trimester of pregnancy cannot be used alone as the predictive factor for fetal macrosomia.

Features of the course and treatment of glaucoma during pregnancy

2020 ◽  
Vol 98 (3) ◽  
pp. 178-184
Author(s):  
T. V. Chernyakova ◽  
A. Yu. Brezhnev ◽  
I. R. Gazizova ◽  
A. V. Kuroyedov ◽  
A. V. Seleznev
Keyword(s):  
Pregnant Women ◽  
Laser Treatment ◽  
Progressive Disease ◽  
Clinical Course ◽  
The Other ◽  
Third Trimester ◽  
The Third ◽  
Chronic Progressive Disease ◽  
Hypotensive Therapy ◽  
Eye Pressure

In the review we have integrated all up-to-date knowledge concerning clinical course and treatment of glaucoma among pregnant women to help specialists choose a proper policy of treatment for such a complicated group of patients. Glaucoma is a chronic progressive disease. It rarely occurs among childbearing aged women. Nevertheless the probability to manage pregnant patients having glaucoma has been recently increasing. The situation is complicated by the fact that there are no recommendations on how to treat glaucoma among pregnant women. As we know, eye pressure is progressively going down from the first to the third trimester, so we often have to correct hypotensive therapy. Besides, it is necessary to take into account the effect of applied medicines on mother health and evaluate possible teratogenic complications for a fetus. The only medicine against glaucoma which belongs to category B according to FDA classification is brimonidine. Medicines of the other groups should be prescribed with care. Laser treatment or surgery may also be a relevant decision when monitoring patients who are planning pregnancy or just bearing a child. Such treatment should be also accompanied by medicines.

Sign in / Sign up

Export Citation Format

Share Document